Accepted Manuscript

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape

Hawazin Faruki, Gregory M. Mayhew, Jonathan S. Serody, D Neil Hayes, Charles M. Perou, Myla Lai-Goldman

PII: S1556-0864(17)30214-9

DOI: 10.1016/j.jtho.2017.03.010

Reference: JTHO 540

To appear in: Journal of Thoracic Oncology

Received Date: 27 September 2016

Revised Date: 4 February 2017

Accepted Date: 7 March 2017

Please cite this article as: Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M, Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape, *Journal of Thoracic Oncology* (2017), doi: 10.1016/j.jtho.2017.03.010.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes

Demonstrate Significant Differences in Tumor Immune Landscape

Hawazin Faruki¹ Gregory M Mayhew¹ Jonathan S Serody² D Neil Hayes² Charles M Perou^{2,3} Myla Lai-Goldman¹

(1)GeneCentric Diagnostics, Durham, NC;
(2)Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC
(3)Department of Genetics, University of North Carolina, Chapel Hill, NC,

*Corresponding Author Hawazin Faruki, DrPH GeneCentric Diagnostics 280 South Mangum Street Suite 350 Durham, NC 27701 919-451-0400 Hawazin@genecentric.com

Keywords: Lung Cancer, Adenocarcinoma, Squamous cell carcinoma, Non Small Cell Lung Cancer, NSCLC, Subtypes, Immune response, PD-L1, Gene Expression.

Disclosures/Conflicts of Interest

HF, GM, MLG, are employees of GeneCentric Diagnostics and are named in 3 pending patents for lung subtyping.

CMP and DNH are Board of Directors Members, equity Stock Holders, and consultants for GeneCentric Diagnostics. They each are also named as inventors on an issued US patent and 3 other pending patents for lung cancer subtyping.

JSS is consultant for GeneCentric Diagnostics.

Download English Version:

https://daneshyari.com/en/article/5701717

Download Persian Version:

https://daneshyari.com/article/5701717

Daneshyari.com